sites where they undergo terminal differentiation. Basophils also develop in the bone marrow, but they circulate as fully functional granulated cells that migrate into tissues in response to inflammation. Both types of cells contain metachromatic granules loaded with histamine, serotonin, and other biologically active products. They express high-affinity IgE receptors (FcεRI) and low-affinity IgG receptors (FcγRIII), as well as receptors for multiple cytokines and growth factors. Upon activation by contact with allergens, the IgE antibodysensitized mast cells release the pharmacologically active mediators stored in their granules, resulting in clinical manifestations of type I hypersensitivity (18) .
Information about the basic biology of mast cells and basophils has been gained largely through studies of bone marrow-derived mast cells (18) and the rat basophilic leukemia cell line (RBL-2H3). The RBL-2H3 cell line has been particularly useful in evaluating the activating and inhibitory potential of PIR-A and PIR-B in transfection studies using chimeric constructs (10, 13) , but the biochemical nature and functional properties of native PIR molecules on the mast cells have not been examined previously. These issues have been addressed in the present studies of cultured mast cells of bone marrow and splenic origin. In parallel studies, the RBL-2H3 cell line was used to refine the definition of PIR-B-inhibitory motifs.
Methods
Mice. Four-to 8-week-old C57BL/6 (H-2 b ), C3H/HeJ (H-2 k ), and BALB/cJ (H-2 d ) mice were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA). C3H/HeJ mice heterozygous for motheaten mutation (me/+), kindly provided by K.A. Siminovitch (Mount Sinai Hospital, Toronto, Ontario, Canada), were bred to generate me homozygous mice (me/me). The me mutation status was identified by genomic PCR using diagnostic primers as described previously (19) .
IL-3-induced mast cell cultures. Bone marrow cells were obtained from the femurs of adult C57BL/6, C3H/He, and BALB/cJ mice. Splenic cells were obtained from neonatal motheaten (me/me) and wild-type (+/+) littermate mice. After lysing the erythrocytes with 0.15 M ammonium chloride solution, bone marrow and splenic cells were cultured at a cell concentration of 2 × 10 5 /ml in RPMI 1640 medium containing 10% FCS (HyClone Laboratories, Logan, Utah, USA), penicillin (100 U/ml), streptomycin (100 µg/ml), 50 µM 2-ME, 1 mM sodium pyruvate, 10 mM HEPES, and mouse rIL-3 (4 ng/ml; R&D Systems Inc., Minneapolis, Minnesota, USA). The marrow-derived nonadherent cells were transferred weekly into new culture flasks over a 4-to 10-week culture interval. Bone marrow mast cell cultures were established from FcεRI α chain-deficient mice (20) and control littermates in some experiments. Splenic nonadherent cells were similarly transferred every 3 days for the first 2-week period, then weekly. Morphology of the cultured cells was examined by staining cell smears with Giemsa or toluidine. The WEHI-3 myeloid cell line obtained from American Type Culture Collection (Rockville, Maryland, USA) was maintained in the same medium without rIL-3.
Immunofluorescence analysis. Cells were incubated with aggregated human IgG to block FcγR before staining for 20 minutes at 4°C with a combination of PE-labeled rat anti-PIR mAb (6C1 clone, γ1κ isotype; ref. 11) and FITC-labeled mAb's specific for the following antigens: CD13, CD69, FcγRII/III, Gr-1, Mac-1/CR3/CD11b, B220/CD45R, or MHC class II (PharMingen, San Diego, California, USA). Isotypematched mAb's with irrelevant specificity (PharMingen) and the IgG fraction from normal rat sera, purified by DE-52 ion exchange cellulose column chromatography, were used as controls. Other reagents included biotinylated rat mAb's specific for c-kit (ACK-2, γ2bκ; ref. 21 Immunoprecipitation analysis of cell surface and intracellular proteins. Viable cells (3 × 10 7 ) were surface radiolabeled with 1 mCi of Na 125 I by lactoperoxidase catalysis and solubilized in ∼500 µl of 1% NP-40 lysis buffer containing various protease inhibitors as described elsewhere (11, 17) . The ultracentrifuged membrane lysates were examined by a solid-phase immunoisolation technique. In brief, microtiter plates precoated with goat anti-rat Ig antibodies (Southern Biotechnology Associates) were incubated with rat anti-PIR (6C1) or isotypematched control mAb before overnight incubation with membrane lysates at 4°C. Other rat anti-PIR mAb's and affinity-purified rabbit anti-PIR antibodies were used in some experiments to coat the microtiter plates. Bound proteins were dissociated by addition of 2% SDS, resolved on SDS-PAGE (10% acrylamide) under reducing and nonreducing conditions, and the dried gels were exposed to x-ray films. In some experiments, mast cells (1.4 × 10 8 ) were metabolically labeled for 18 hours with a mixture of 35 S-Met and 35 S-Cys (3 mCi, 43.5 TBq/mmol; NEN Life Science Products Inc., Boston, Massachusetts, USA) and 35 S-Cys (500 µCi, 39.8 TBq/mmol; NEN Life Science Products Inc.), lysed, and incubated with streptavidin-coupled Sepharose 4B beads containing biotinylated phosphopeptides (15 mers) that correspond to the PIR-B cytoplasmic tyrosine (Y713, Y742, Y770, Y794, Y824) regions or to the FcγRIIB ITIM, before SDS-PAGE analysis as described previously (13) .
Protein blot analysis. Cells (3 × 10 7 ) were solubilized in lysis buffer supplemented with 2 mM sodium orthovanadate and 50 mM sodium fluoride (17) . Proteins in the cell lysates that were immunoadsorbed with anti-PIR or control mAb's or with streptavidin-coupled beads containing the biotinylated PIR-B phosphopeptides were resolved on SDS-PAGE and transferred onto nitrocellulose membranes by electroblotting. After soaking in 3% BSA in PBS containing 0.05% Tween-20, membranes were incubated with HRP-labeled mouse anti-phosphotyrosine mAb (4G10; Upstate Biotechnology Inc., Lake Placid, New York, USA) or with rabbit antibodies specific for protein tyrosine phosphatase SHP-1 (Upstate Biotechnology Inc.) or SHP-2 (Santa Cruz Biotechnology, Santa Cruz, California, USA) or for inositol polyphosphate 5-phosphatase SHIP (Santa Cruz Biotechnology). In some experiments, mouse anti-SHP-2 mAb (Transduction Laboratories, Lexington, Kentucky, USA) and HRP-labeled goat anti-mouse IgG antibody (Southern Biotechnology Associates) were used. For rabbit antibodies, HRP-labeled goat anti-rabbit Ig antibody (0.1 µg/ml; Southern Biotechnology Associates) was used as a developing reagent before visualization by enhanced chemiluminescence employing the oxidation of luminol in the presence of phenols (Amersham Life Science, Buckinghamshire, United Kingdom). Membranes were reblotted with rabbit anti-PIR antiserum (1:4,000 dilution) to detect PIR-A and PIR-B molecules.
RT-PCR analysis. Total RNA was extracted from cultured mast cells and control cell lines (10 7 cells) by the TriReagent method (Molecular Research Center Inc., Cincinnati, Ohio, USA). Two micrograms of RNA were converted to first-strand cDNA with oligo (dT) [12] [13] [14] [15] [16] [17] [18] primers and SuperScript RNase H -RT (Life Technologies Inc., Rockville, Maryland, USA), and amplified with a common forward primer (5′-CCTGTGGAGCTCA-CAGTCTCAG-3′), and the PIR-A specific (5′-CCCA-GAGTGTAGAACATTGAAGATG-3′) or PIR-B specific (5′-GTGTTCAGTTGTTCCCTTGACATGA-3′) reverse primers. These primers correspond to the 3′ end of D6 of PIR-A and PIR-B and to the cytoplasmic regions of PIR-A and PIR-B, respectively, and yield fragments of 252 bp for PIR-A and 470 bp for PIR-B (1). Each amplification reaction included 30 cycles of denaturation at 94°C for 1 minute, annealing at 60°C for 1 minute, and extension at 72°C for 1 minute. A final extension was performed at 72°C for 5 minutes. Amplification of actin transcripts with the primers (5′-ATTGAACATGGCA-TTGTTACC-3′ and 5′-GGCATACAGGGACAGCACAGC-3′) was also performed as a control. Amplified products were electrophoresed in 1.5% agarose and stained with ethidium bromide.
Ca 2+ mobilization analysis. Intracellular Ca 2+ concentrations were measured after PIR and/or FcεRI crosslinkage on mast cells as described elsewhere (13) . Briefly, mast cells were loaded with Indo-1/AM (1 µg/ml; Calbiochem-Novabiochem Corp., San Diego, California, USA) in the presence or absence of rat IgE anti-DNP mAb (1 µg/ml) for 30 minutes at 37°C, resuspended at 10 6 cells/ml either in HBSS containing 5% FCS or Ca 2+ -free HBSS containing 1 mM MgCl 2 and were incubated first with F(ab′) 2 fragments of the rat anti-PIR mAb (10.1 clone; γ2bκ; 20 µg/ml) and then with F(ab′) 2 fragments of rabbit anti-rat Ig antibody (50 µg/ml; Southern Biotechnology Associates) as a cross-linker. Purity of the F(ab′) 2 reagents was established by SDS-PAGE analysis. An intact rat mAb (1D6 clone; γ2aκ), against an undefined cell surface component on mouse cells, including mast cells, was used as a control for the 10.1 anti-PIR mAb. The 395/510 nm fluorescence ratio for the dye-loaded viable cells was determined with a FACStar Plus flow cytometer (Becton Dickinson Immunocytometry Systems) equipped with an Enterprise laser (Coherent Laser Group, Santa Clara, California, USA) regulated at 40 mW UV.
Serotonin-release assay. IgE-mediated serotonin release assay was performed according to methods described previously (13) , with the following minor modifications. IL-3-induced mast cells (1 × 10 6 cells/ml) were incubated with 5-[1,2-3 H(N)]-hydroxytryptamine binoxalate (5 µCi/ml; 37,000 MBq; NEN Life Science Products Inc.) for 5 hours at 37°C, washed, and reincubated for an additional 1 hour at 37°C to reduce background radioactivity. Thirty microliters of 3 H-serotonin-loaded mast cells (1.4 × 10 7 cells/ml) were plated in 96-well plates that contained 10 µl of rat IgE anti-DNP mAb (25 µg/ml) and 10 µl of various concentrations (0.5-50 µg/ml) of F(ab′) 2 fragments of rat anti-PIR mAb in triplicate, incubated for 30 minutes at 4°C, washed, and resuspended in 25 µl of culture medium. The 1D6 rat mAb (intact form) was used as a control antibody. Antibody-primed mast cells were challenged with 25 µl of F(ab′) 2 fragments of rabbit anti-rat Ig antibody (40 µg/ml) for 30-60 minutes at 37°C. In other experiments, DNP-coupled human serum albumin and goat anti-rat IgG antibody were used to aggregate separately the IgE and PIR receptors. The reactions were terminated by adding 50 µl of cold HBSS and centrifugation. 3 H-Serotonin in the supernatants was measured by a liquid scintillation counter. The total incorporation of 3 H-serotonin was determined by lysis of unprimed cells with 1% SDS/1% NP-40, and the percent of serotonin release was defined as: 100 × (cpm of supernatants ÷ cpm of total incorporation). For cells transfected with FcγRIIB/PIR-B chimeric constructs, mouse IgE anti-TNP mAb (2682-1), rat anti-mouse FcγRII/III mAb (2.4G2; γ2bκ), and F(ab′) 2 fragments of goat antimurine Ig antibodies (Immunotech, Marseille, France) were used to ligate FcεRI and FcγRIIB/PIR-B as described elsewhere (13) .
Constructs. cDNA constructs generated from a pNTNeo plasmid included a chimeric cDNA encoding the extracellular, transmembrane, and the first six amino acids (KKKQVP; one-letter code) of the cytoplasmic tail of the mouse FcγRIIB1, fused with the cytoplasmic region of the mouse PIR-B (FcγRIIB/PIR-B) as described previously (13) . The initial FcγRIIB in pNT-Neo vector was provided by P. Bruhns and M. Daëron (Institut Curie, Paris, France; ref. 23 ). Deletion and point-mutation constructs were generated by PCRdirected mutagenesis of the FcγRIIB/PIR-B construct. Each point mutation involved a tyrosine (Y) replacement by phenylalanine (F). Fidelity of the constructs was verified by sequencing.
Transfection. The RBL-2H3 rat basophilic leukemia cell line cultured in DMEM supplemented with 10% FCS, penicillin (100 IU/ml) and streptomycin (100 µg/ml) was transfected with different cDNA constructs by electroporation as described previously (13) . Stable transfectants were established by culture in the presence of G418 (1 mg/ml).
Results
Characterization of mast cells derived from bone marrow and splenic progenitors. Nonadherent bone marrow cells from normal adult mice (BALB/c, C57BL/6, C3H/He) and from FcεRI α chain-deficient (FcεRIα -/-) mice were cultured with rIL-3 for 4-10 weeks to generate mast cells; more than 95% of the cells in these cultures expressed high levels of the c-kit receptor tyrosine kinase (CD117) and the capacity to bind IgE ( Figure 1 ). As anticipated, the c-kit + mast cells from FcεRIα -/-mice did not exhibit IgE binding. Morphological analysis of the cultured cells indicated the presence of toluidine blue-stained granules characteristic of basophils and mast cells. The cells also expressed aminopeptidase N (CD13), lowaffinity receptors for IgG (FcγRII/III) and the CD69 early-activation antigen, but were negative for Mac-1/CD11b, B220/CD45R, MHC class II, granulocyte differentiation antigen (Gr-1), and the CD40 TNF superfamily member, a phenotypic profile that is characteristic for IL-3-induced, bone marrow-derived mast cells (18, 24) . Importantly for our studies, the IL-3-induced mast cells from normal and FcεRIα -/-mice expressed cell surface PIR proteins at relatively high levels ( Figure 1, a and b) .
Mast cell cultures were also derived from neonatal splenic progenitors in SHP-1-deficient motheaten (me/me) mice and control littermates because the me/me defect leads to early death. Like the mast cells generated from adult bone marrow, the spleen-derived mast cells expressed cell surface PIR as well as c-kit, CD13, FcγRII/III, CD69, IgE binding capacity, and intracellular metachromatic granules (Figure 1, c and d) .
Predominant expression of constitutively tyrosine-phosphorylated PIR-B on mast cells. In a previous analysis, both PIR-A and PIR-B transcripts were found to be expressed by the P815 mast cell line, although this cell appeared to express higher levels of PIR-B transcripts than PIR-A transcripts. When a similar RT-PCR analysis was conducted for the bone marrow-derived mast cells, both PIR-A and PIR-B transcripts were found in roughly equal abundance (Figure 2a ).
An immunoprecipitation analysis of radiolabeled cell surface proteins was then performed with the 6C1 anti-PIR antibody. This antibody recognizes a common epitope on the D1 and D2 Ig-like ectodomains of PIR-A and PIR-B proteins that can be distinguished on the basis of their relative molecular masses (11) . To compare the array of PIR molecules expressed on the different types of cells, nonadherent mast cells and adherent macrophages in the bone marrow-derived cultures were separated and their cell surface PIR proteins were analyzed along with those expressed by splenocytes, the majority of which were B lymphocytes. Both the 120-kDa PIR-B and 85-kDa PIR-A were precipitated from membrane lysates of surface iodinated splenocytes and macrophages, whereas only PIR-B molecules were detected in the membrane lysates of mast cells (Figure 2b ). Given that FcRγc is required for the expression of functional PIR-A, limited FcRγc availability due to competition with the FcεRI could account for the paucity of cell surface PIR-A expression. To test this possibility, the FcεRIα -/-mice-derived mast cells were examined for their surface PIR expression. The results again indicated predominant expression of PIR-B on the surface of FcεRIα -/-mast cells, thereby suggesting that a limitation in the availability of FcRγc is unlikely to be the basis for the paucity of surface PIR-A on mast cells (Figure 2c, upper panel) . The predominance of cell surface PIR-B was also observed for mast cells derived from splenic progenitors in neonatal me/me mice and control littermates (Figure 2c, lower panel) The PIR-B molecules on mast cells were also found to be constitutively tyrosine phosphorylated and to be associated with SHP-1 protein tyrosine phosphatase, except in mast cells from me/me mice. SHP-2 was not found to be associated with PIR-B in mast cells (data not shown), consistent with the results of an earlier analysis of PIR-B molecules on splenic B lymphocytes and macrophages (17) .
PIR-B-mediated inhibition of FcεRI-induced Ca 2+ mobilization and serotonin release. Because mast cells preferentially express PIR-B on their cell surfaces, examination of the functional consequence of PIR-A/PIR-B ligation with a nondiscriminative antibody is a more straightforward analysis than for the B lymphocytes and myeloid cells that express both PIR-A and PIR-B molecules on their cell surface. The effects of PIR-B cross-linkage on FcεRI-mediated Ca 2+ mobilization were examined initially as an early indicator of the cellular response. Ligation of FcεRI on mast cells induced an immediate Ca 2+ release from intracellular pools, followed by a sustained increase that may reflect the influx of extracellular Ca 2+ . Although PIR ligation alone had no demonstrable effect on intracellular Ca 2+ levels, coligation of FcεRI and PIR inhibited IgEinduced Ca 2+ mobilization (Figure 3, upper panel) . When this experiment was repeated in Ca 2+ -free media, IgE-induced Ca 2+ mobilization was again inhibited by PIR-B and FcεRI coligation (data not shown), thereby confirming that the PIR-B inhibition affects Ca 2+ release from the intracellular pool.
When the effects of PIR-B cross-linkage on FcεRI-mediated serotonin release were evaluated, PIR coligation with the FcεRI inhibited this mast cell response in a dose-dependent manner (Figure 4, left panel) . The inhibition was observed only when the PIR-B and FcεRI were brought into physical proximity by ligation with a common secondary reagent. In a test of the PIR-B specificity of the inhibitory effect, coligation of FcεRI with an unrelated cell surface molecule did not inhibit IgE-mediated serotonin release. Separate ligation of cell surface PIR-B and FcεRI with individual secondary reagents also did not result in inhibition of the IgEmediated serotonin release, and ligation of PIR-B alone did not induce serotonin release (data not shown). These findings collectively demonstrate the functional potential of PIR-B as a negative regulator of IgE-mediated mast cell activation.
SHP-1 is dispensable in the PIR-B inhibitory activity.
In native B cells and in transfected cell models, PIR-B has been shown to recruit the SHP-1 protein tyrosine phosphatase (10, (13) (14) (15) . To test the requirement for SHP-1 in the PIR-B-mediated inhibition of FcεRI signaling, we examined mast cells from SHP-1-deficient motheaten (me/me) mice and normal littermate (+/+) controls. To our surprise, IgE antibody-mediated intracellular Ca 2+ When a search was conducted for the association of PIR-B with another protein tyrosine phosphatase in the motheaten-derived mast cells, the approximately 72-kDa SHP-2 protein could not be found in PIR-B immunoprecipitates examined with two different SHP-2 specific antibodies, although SHP-2 protein is abundant in the mast cells and can be shown to bind to phosphopeptides representative of the two carboxy terminal PIR-B ITIMs (ref. 13; see below). To examine the possibility that SHP-2 may be recruited by PIR-B only after receptor cross-linkage in the absence of SHP-1, PIR-B immunoprecipitates were examined before and after PIR crosslinkage on the mast cells. However, SHP-2 association with PIR-B could not be detected even after receptor ligation in these experiments (data not shown). The SHIP inositol polyphosphate 5-phosphatase was also not found to be associated with the PIR-B molecules in the mast cells from me/me and control mice. These unanticipated results indicate that the PIR-B-mediated inhibition of IgE-induced responses in mast cells is not dependent on SHP-1, and also imply lack of dependence on SHP-2 or SHIP interaction.
Rather, the data raise the possibility that another, yet unidentified, inhibitory signaling element can participate in the PIR-B inhibitory function.
A third tyrosine-based motif in the PIR-B cytoplasmic tail mediates inhibitory function. The PIR-B protein contains five cytoplasmic tyrosine residues, four of which, Y713 (SLYASV), Y742 (ETYAQV), Y794 (VTYAQL), and Y824 (SVYATL), reside within ITIM-like sequences (I/V/L/S-x-Y-x-x-V/L), whereas the other tyrosine, Y770 (TEYEQA), does not reside in an ITIM consensus sequence. In previous studies (13) , phosphopeptides corresponding to the Y794 tyrosine-and Y824 tyrosine-based motifs were shown to bind SHP-1 and SHP-2 phosphatases derived from a B cell line, whereas phosphopeptides representing the other two ITIM candidates failed to bind either phosphatase. To test whether these relationships held true for mast cells, the cellular proteins in lysates of metabolically labeled and unlabeled mast cells were incubated with phosphopeptides containing the PIR-B tyrosine residues (Y713, Y742, Y770, Y794, Y824) or the FcγRIIB ITIM as a control. Although the FcγRIIB phosphopeptide bound multiple SHIP isoforms as well as SHP-1 and SHP-2, the two carboxy terminal PIR-B ITIM phosphopeptides (Y794 and Y824) again were found to bind both SHP-1 and SHP-2. Although the Y742 phosphopeptide failed to bind SHIP, SHP-1 or SHP-2, a protein of approximately 120 kDa was instead found to be associated with this ITIM candidate ( Figure 5) .
Previous transfection studies have indicated that the two carboxy terminal PIR-B ITIMs (Y794 and Y824) are responsible for most, but not all, of the inhibitory capacity of PIR-B (13, 14) . To determine whether the
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The . Antibody-primed cells were then triggered with F(ab′) 2 fragments of rabbit anti-rat Ig antibody as a cross-linker, and the 3 H-serotonin release was measured as described in Methods. The standard deviation from the mean (circle) is indicated by bars only for the points at which this value (1 SD) is greater than the circle radius.
Figure 5
Analysis of mast cell proteins binding to PIR-B ITIM. Left panel: Metabolically labeled mast cell proteins were solubilized in 1% NP-40 lysis buffer before incubation with streptavidin-coupled beads bearing biotinylated 15-mer peptides corresponding to the mouse FcγRIIB ITIM (tyrosine-phosphorylated, pY, or tyrosine-nonphosphorylated, Y, as controls) and each of the tyrosine-phosphorylated and biotinylated PIR-B ITIM (pY713, pY742, pY770, pY794, pY824). Bound materials were resolved by SDS-8% PAGE under nonreducing conditions before exposure to x-ray films. Arrowhead indicates 120-kDa protein band precipitated by the pY742 phosphopeptide. Right panel: Proteins isolated from mast cell lysates with the same phosphopeptides were resolved by SDS-PAGE before transfer onto membranes and immunoblotting with antibodies specific for SHP-1, SHP-2, or SHIP before visualization by enhanced chemiluminescence.
other two tyrosine-based motifs, centered around Y713 and Y742, can also mediate PIR-B inhibitory activity, four additional chimeric constructs were prepared: (a) One encodes a short PIR-B cytoplasmic tail with a carboxy terminal deletion from five amino acids after Y742 (YY); (b) the second encodes a similar short PIR-B cytoplasmic tail with a point mutation of Y742F (YF); (c) the third includes three point mutations, Y713F, 794F, and Y824F, to allow evaluation of the role of Y742 (FYFF); and (d) the fourth encodes the shortest PIR-B cytoplasmic tail, rendered tyrosine-free by deleting the carboxy terminus from position 712 onward (∆712). These chimeric constructs were transfected into RBL-2H3 cells, and the resultant stable transfectants were shown by immunofluorescence to express levels of FcγRIIB/PIR-B chimeric receptors comparable to that of the wild-type transfectant, except for the YF transfectant, where the FcγRIIB/PIR-B level was higher ( Figure 6 ). The cell surface levels of endogenous FcεRI on the different transfectants were not altered. These chimeric receptor transfectants were examined for their potential to inhibit the FcεRI-mediated serotonin release. As previously shown (13) , coligation of FcεRI and the wild-type (YYYY) chimeric receptor effectively inhibited the IgE-mediated serotonin release (Figure 7) . The YY-type chimeric receptor could also mediate significant inhibition over a wide range of IgE stimulation dosages, whereas the YF type chimeric receptor did not, even though the YF transfectant expressed higher levels of chimeric receptors than did the YY transfectant. The FYFF-type chimeric receptor mediated inhibition to a similar degree as did the YY-type chimeric receptor, thereby implicating the Y742-based motif in the inhibition. No inhibitory capability could be demonstrated for the ∆712-type chimeric receptor. These findings demonstrate that three of the four PIR-B ITIM candidates, namely the Y742-, Y794-, and Y824-based motifs, have inhibitory capability. The inhibitory function of the newly verified Y742-based ITIMs may involve the associated p120 molecule (see Figure 5 ).
Discussion
Several unanticipated features of the PIR-B inhibitory potential in mast cells are indicated in these studies. Although mast cells apparently produce PIR-A and PIR-B in similar amounts, the latter is preferentially expressed on the mast cell surface as a constitutively tyrosine phosphorylated molecule. Although the SHP-1 protein tyrosine phosphatase is normally associated with PIR-B molecules, surprisingly, this phosphatase appears to be entirely dispensable in the PIR-B-mediated inhibition of IgE antibody-mediated mast cell activation. A third functional PIR-B ITIM identified in this study, the Y742-based ETYAQV motif, that failed to bind either protein tyrosine phosphatases (SHP-1 and SHP-2) or inositol polyphosphate 5-phosphatase (SHIP) (8, 10, 13) , was found to associate with another potential regulatory element, a presently unidentified protein of approximately 120 kDa.
Mast cells derived from bone marrow or splenic progenitors were found to produce the PIR-B and PIR-A transcripts in comparable levels, but an analysis of their cell surface expression indicated a striking prevalence of PIR-B. PIR-A could not be detected on the mast cells, whereas PIR-B was easily and consistently detected on the cell surface. Previous studies have indicated that an association with FcRγc homodimers is required for the normal expression of PIR-A molecules on the cell surface (11) . As FcRγc is also an essential component of the high-affinity IgE receptor complex, FcεRI (25) , an inability to compete efficiently with the FcεRI for a limited supply of FcRγc dimers could explain the paucity of PIR-A molecules that reach the mast cell surface. Indeed, previous studies have suggested competition between FcεRI and FcγRIII for limiting amounts of FcRγc (26, 27) . Functional FcγRIII is not expressed on mast cells, as it is not efficiently associated with the FcRγc and thus degraded intracellularly (26) . Absence of FcεRI α chain thus results in upregulation of FcγRIII-dependent mast cell responses (27) . However, we found that FcεRI α chain-deficient mast cells also lack detectable cell surface PIR-A expression, thereby suggesting that other regulatory mechanisms may account for the paucity of PIR-A on mast cells. The IL-3-induced mast cells should provide an ideal cell source to determine the regulatory mechanisms affecting the equilibrium of cell surface PIR-A and PIR-B expression.
The integrity of the PIR-B-mediated inhibition of IgE triggered Ca 2+ mobilization and serotonin release in SHP-1-deficient mast cells was also unanticipated, because previous studies have suggested that the inhibitory activity of PIR-B is mediated primarily through its association with SHP-1 (13, 14, 17) . The possibility was therefore considered that the inhibition seen in me/me mast cells reflected artifactual co-cross-linkage of PIR-B with the FcγRIIB via the intact antibodies used for coligating PIR-B and FcεRI. FcγRIIB has its own ITIM motif, through which it can interact with the SHIP inositol polyphosphate 5-phosphatase to inhibit cell activation (28) (29) (30) . However, this explanation of our results was rendered unlikely by the observations that (a) intact IgG molecules could not be detected in the F(ab′) 2 preparations of rat anti-PIR and rabbit anti-rat Ig antibodies that were used for receptor coligation, (b) inhibitory responses generated by PIR-B and FcγRIIB are dissimilar in that PIR-B-mediated inhibition involves a blockage of Ca 2+ release from intracellular stores (see Figure 3) , whereas FcγRIIB-mediated inhibition involves blockage of Ca 2+ influx (28) , and (c) the coligation of FcεRI and an unrelated molecule with an intact antibody failed to inhibit the IgE-mediated Ca 2+ mobilization and serotonin release. The alternative possibility that the inhibitory activity of PIR-B could directly involve SHIP is rendered unlikely by the inability to identify an association between these two molecules in the present studies or in earlier analyses (13) (14) (15) 17) .
Protein tyrosine phosphatase activity mediated by SHP-2 is a third possible explanation for the PIR-B inhibitory effect observed in SHP-1-deficient mast cells. In a previous analysis using a B cell line, we observed that SHP-1 and SHP-2 could bind to phosphopeptides corresponding to the two carboxyterminal ITIM (Y794 and Y824) in the PIR-B cytoplasmic tail (13) . The present studies indicate that the PIR-B Y794 and Y824 phosphopeptides also associate with SHP-1 and SHP-2 in mast cells. However, in normal mast cells, splenic lymphocytes (17) , and RBL-2H3 cells transfected with chimeric receptor (extracellular FcγRIIB/PIR-B cytoplasmic tail) constructs (13), we have consistently observed the association of PIR-B with SHP-1, and not with SHP-2. Nevertheless, when Maeda et al. used PIR-B constructs to transfect DT-40 chicken B cells deficient in SHP-1, SHP-2, or both, their results suggested that both the SHP-1 and SHP-2 phosphatases may participate in PIR-B-mediated inhibition (14) . Although this interpretation could also explain our results with the motheaten (me/me) mast cells, PIR-B-associated SHP-2 molecules were not demonstrable in mast cells from normal mice or the SHP-1-deficient motheaten mice. This raises the possibility that PIR-B signaling elements other than SHP-1, SHP-2, and SHIP contribute to the inhibitory function. Consistent with this hypothesis, Maeda et al. found residual PIR-B inhibitory activity in the SHP-1 and SHP-2 double-deficient DT40 cells, leading them to invoke the involvement of an additional SH2-containing protein(s) in mediating the PIR-B inhibitory signal (14) . 4G2 rat anti-FcγRII/III mAb (20 µg/ml). F(ab′) 2 fragments of goat anti-murine Ig antibody (50 µg/ml) were used as a cross-linker. A representative result is shown as a mean ± 1 SD (if the SD values are greater than the radius of circles) from at least three independent experiments. Statistical analysis revealed that inhibition is significant for IgE at 1:1,000 and 1:300 dilutions in a, b, and d (data not shown).
